Literature DB >> 7082863

Renal plasma clearance: a valuable marker in myelomatosis.

O P Hansen, A Drivsholm.   

Abstract

Forty-two consecutive patients with untreated myelomatosis (MM) formed the basis of settling the validity of measuring the renal plasma clearance (RPC), either indirectly using the serum creatinine or directly using the glomerular filtration rate (GFR) when studying anaemia, calcium metabolism, proteins in serum and urine, and prognosis. Patients without light chain excretion in the urine had a higher GFR (P less than 0.01) than patients with light chain excretion. The haemoglobin concentration (Hb) was strongly correlated (P less than 0.001) to both, serum creatinine and GFR. Patients with normal serum concentrations of the physiological immunoglobulins had higher Hb (P less than 0.01) than patients with reduced serum immunoglobulins. Patients with serum calcium greater than 3.00 mmol/1 had additional reduced GFR compared with the other myeloma patients. The serum parathyroid hormone was decreased (P less than 0.01) and inversely correlated to the GFR. Patients with increased serum creatinine, reduced GFR or with osteolytic bone lesions had a decreased survival rate. The study shows that the major factor in prediction of Hb and prognosis in patients with MM is the RPC expressed either as the serum creatinine or the GFR. In addition, the significant correlations between the GFR and the other variables in MM assessed the RPC to be a useful and valuable marker in studies of anaemia, protein and calcium metabolism and prognosis in MM.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7082863     DOI: 10.1007/BF00320493

Source DB:  PubMed          Journal:  Blut        ISSN: 0006-5242


  35 in total

1.  Kidney function studies in myelomatosis.

Authors:  J R MYHRE; E K BRODWALL
Journal:  Scand J Clin Lab Invest       Date:  1957       Impact factor: 1.713

2.  The renal handling of parathyroid hormone. Role of peritubular uptake and glomerular filtration.

Authors:  K J Martin; K A Hruska; J Lewis; C Anderson; E Slatopolsky
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

3.  Selective uptake of intact parathyroid hormone by the liver: differences between hepatic and renal uptake.

Authors:  K Martin; K Hruska; A Greenwalt; S Klahr; E Slatopolsky
Journal:  J Clin Invest       Date:  1976-10       Impact factor: 14.808

4.  Bence Jones proteinuria in benign monoclonal gammapathies. Incidence and characteristics.

Authors:  F Dammacco; J Waldenström
Journal:  Acta Med Scand       Date:  1968-11

5.  Rocket immunoelectrophoresis.

Authors:  B Weeke
Journal:  Scand J Immunol Suppl       Date:  1973

6.  Structure and function of the kidney in multiple myeloma.

Authors:  G E Schubert; J Veigel; K Lennert
Journal:  Virchows Arch A Pathol Pathol Anat       Date:  1972

7.  Treatment of myeloma. Comparison of melphalan, chlorambucil, and azathioprine.

Authors: 
Journal:  Arch Intern Med       Date:  1975-01

8.  Prognostic factors in multiple myeloma.

Authors:  R Alexanian; S Balcerzak; J D Bonnet; E A Gehan; A Haut; J S Hewlett; R W Monto
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

9.  Interrelationships between Vitamin B12 and folic acid in myelomatosis: cobalamin coenzyme and tetrahydrofolic acid function.

Authors:  O P Hansen; A Drivsholm; E Hippe; E Quadros; J C Linnell
Journal:  Scand J Haematol       Date:  1978-04

10.  Clinical staging in multiple myeloma.

Authors:  R K Woodruff; J Wadsworth; J S Malpas; J S Tobias
Journal:  Br J Haematol       Date:  1979-06       Impact factor: 6.998

View more
  1 in total

1.  [Analysis of prognostic factors in plasmacytoma].

Authors:  W Gassmann; T Haferlach; N Schmitz; W Kayser; H H Euler; J Drews; H Löffler
Journal:  Klin Wochenschr       Date:  1984-10-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.